Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha ® ...
A statin isn’t the only answer anymore to lowering cholesterol. The lipid-reducing medicines, among the most widely prescribed drugs in the U.S., have been a mainstay of heart-disease prevention and ...
Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the fourth ...
As the first storms of the season start to hit the Mountain West and parts of the West Coast, it’s hard not to get excited for the impending winter. Memories of winter’s past always fill my brain as I ...
Life&Style Weekly on MSN
The Surprising New Side Effect Of Taking GLP-1 Medications
While many patients experience common side effects from GLP-1 medications — such as nausea and bloating, new research has ...
Patients who switched from the brand-name antidepressant Wellbutrin XL 300 to generic bupropion saw panic attacks, headaches, ...
A new study compared the effects of 30 drugs on cholesterol, blood pressure and weight gain. By Chloe W. Shakin A new large-scale analysis found that the short-term cardiovascular and metabolic side ...
ZME Science on MSN
Researchers Assessed Antidepressants by Side Effects and Found Some Big Differences
The “ranking” of antidepressants depends entirely on which side effect is most important to you. Some drugs, like the ...
Antidepressants vary greatly in the side effects they cause – from weight gain to weight loss and blood pressure changes. This may need to be taken into account when doctors decide which of the many ...
A new large-scale analysis found that the short-term cardiovascular and metabolic side effects of antidepressants vary widely by drug, but the ones most commonly prescribed in the United States are ...
In the study, published Tuesday in the journal The Lancet, researchers analyzed more than 58,000 participants to compare 30 antidepressants with a placebo for an average of eight weeks, finding ...
London Metal Exchange CEO Matt Chamberlain tells CNBC that there is a medium term demand driver for copper, but that most of the recent price action has been driven by the supply side. Social Security ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results